Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 2/20 | 0.83 |
| ▸ | AURKA | O14965 | 2/20 | 0.71 |
| ▸ | PRKAA1 | Q13131 | 7/20 | 0.70 |
| ▸ | PRKAA2 | P54646 | 6/20 | 0.70 |
| ▸ | KDR | P35968 | 10/20 | 0.69 |
| ▸ | TLK2 | Q86UE8 | 3/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 11/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.68 |
| ▸ | FLT1 | P17948 | 2/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.67 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.67 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.67 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL859966 | 0.91 | ALK (1.00) | ALKAURKAPRKAA1PRKAA2KDR | |
| SCHEMBL859965 | 0.91 | ALK (1.00) | ALKAURKAPRKAA1PRKAA2KDR | |
| SCHEMBL1081676 | 0.90 | ALK (0.82) | ALKAURKAPRKAA1PRKAA2KDR | |
| SCHEMBL30733142 | 0.90 | ALK (0.82) | ALKAURKAPRKAA1PRKAA2KDR | |
| SCHEMBL12329173 | 0.90 | ALK (0.82) | ALKAURKAPRKAA1PRKAA2KDR | |
| SCHEMBL18814394 | 0.90 | ALK (0.82) | ALKAURKAPRKAA1PRKAA2KDR | |
| SCHEMBL29486525 | 0.90 | ALK (0.82) | ALKAURKAPRKAA1PRKAA2KDR | |
| SCHEMBL17503076 | 0.90 | ALK (0.82) | ALKAURKAPRKAA1PRKAA2KDR | |
| SCHEMBL16085063 | 0.89 | ALK (0.80) | ALKAURKAPRKAA1PRKAA2KDR | |
| SCHEMBL13960772 | 0.88 | ALK (0.78) | ALKAURKAPRKAA1PRKAA2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206163-B2 | Process for the preparation of sunitinib and its acid addition salts thereof | LAURUS LABS PRIVATE LTD. (IN) | 2015-12-08 | — | — | US | disclosed |
| US-9206163-B2 | Process for the preparation of sunitinib and its acid addition salts thereof | LAURUS LABS PRIVATE LTD. (IN) | 2015-12-08 | — | — | US | disclosed |
| US-20150025252-A1 | PROCESS FOR THE PERPARATION OF SUNITINIB AND ITS ACID ADDITION SALTS THEREOF | LAURUS LABS LIMITED (IN) | 2015-01-22 | — | — | US | disclosed |
| US-20150025252-A1 | PROCESS FOR THE PERPARATION OF SUNITINIB AND ITS ACID ADDITION SALTS THEREOF | LAURUS LABS LIMITED (IN) | 2015-01-22 | — | — | US | disclosed |
| US-8846953-B2 | Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles | SCINOPHARM TAIWAN, LTD. (TW) | 2014-09-30 | — | — | US | disclosed |
| US-8846953-B2 | Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles | SCINOPHARM TAIWAN, LTD. (TW) | 2014-09-30 | — | — | US | disclosed |
| US-8524709-B2 | Kinase inhibitor compounds | TYROGENEX, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130190512-A1 | PROCESSES FOR THE PREPARATION OF 3-(PYRROL-2-YL)METHYLENE)-2-PYRROLONES USING 2-SILYLOXY-PYRROLES | SCINOPHARM TAIWAN, LTD. (TW) | 2013-07-25 | — | — | US | disclosed |
| US-20130190512-A1 | PROCESSES FOR THE PREPARATION OF 3-(PYRROL-2-YL)METHYLENE)-2-PYRROLONES USING 2-SILYLOXY-PYRROLES | SCINOPHARM TAIWAN, LTD. (TW) | 2013-07-25 | — | — | US | disclosed |
| US-20110224212-A1 | KINASE INHIBITOR COMPOUNDS | TYROGENEX, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| EP-1670785-B1 | SALTS AND POLYMORPHS OF A PYRROLE-SUBSTITUTED INDOLINONE COMPOUND | PHARMACIA & UPJOHN CO LLC (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20100160646-A1 | PROCESSES FOR PREPARING SUNITINIB AND SALTS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-06-24 | — | — | US | disclosed |
| US-20090247767-A1 | PROCESSES FOR PREPARING SUNITINIB AND SALTS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-10-01 | — | — | US | disclosed |
| WO-2008033743-A1 | SUBSTITUTED 2-INDOLINONE AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-7247627-B2 | non-hygroscopic, crystalline anhydrous maleate salt of 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene) methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide | PHARMACIA & UPJOHN COMPANY (US) | 2007-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190512-A1 | PROCESSES FOR THE PREPARATION OF 3-(PYRROL-2-YL)METHYLENE)-2-PYRROLONES USING 2-SILYLOXY-PYRROLES | SKP2, SDHA, MDH2 | ALK 530/4885AURKA 52/4885PRKAA1 2135/4885 |
| US-20100160646-A1 | PROCESSES FOR PREPARING SUNITINIB AND SALTS THEREOF | KDR, ABL1, FLT4 | ALK 72/4885AURKA 123/4885PRKAA1 1049/4885 |
| US-20090247767-A1 | PROCESSES FOR PREPARING SUNITINIB AND SALTS THEREOF | KDR, ABL1, FLT4 | ALK 72/4885AURKA 123/4885PRKAA1 1049/4885 |
| US-20110224212-A1 | KINASE INHIBITOR COMPOUNDS | MAP3K1, MAP3K20, MAP3K2 | ALK 479/4885AURKA 335/4885PRKAA1 59/4885 |
| US-20150025252-A1 | PROCESS FOR THE PERPARATION OF SUNITINIB AND ITS ACID ADDITION SALTS THEREOF | SUN2, FGFR3, FGFR4 | ALK 1754/4885AURKA 141/4885PRKAA1 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.